Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )

Clinical trial NCT07720921 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07720921
Sponsor: Peking University First Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Urothelial Carcinoma of the Renal Pelvis and Ureter Neoadjuvant Therapy

Start date: 2026-08-01
Primary completion: 2027-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.